---
title: "NHS National Generic Pharmaceuticals Wave 13"
ocid: "ocds-h6vhtk-02be28"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02be28"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-02be28.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-02be28.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)"
published: "2022-01-14"
---

# NHS National Generic Pharmaceuticals Wave 13

Buyer: THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)  
Current stage: Award  
OCID: ocds-h6vhtk-02be28

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02be28)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-02be28.json)

## Summary

The NHS Commissioning Board, operating under the name of NHS England, has initiated a tender process for the "NHS National Generic Pharmaceuticals Wave 13." This procurement, classified under the pharmaceutical products category (CPV code: 33600000), is set within the goods procurement sector. The tender period is currently active, with the submission deadline set for 26th July 2021. The framework agreement is designed to run a maximum of 28 months, with options for extensions at the Authority's discretion, covering call-off periods for various pharmaceutical products from March 2022 to May 2024.

This procurement presents significant opportunities for pharmaceutical companies, particularly those engaged in supplying generic medications. Businesses of all sizes, including both large pharmaceutical manufacturers and SMEs, are encouraged to participate. The competitive nature of the tender allows for a diverse range of companies, from established industry leaders to innovative market entrants, to showcase their products and services, supporting the growth of their business within the healthcare sector.

## Notice

Potential periods of call-offs under the framework agreement:

Transition (Everolimus)
CESW: 1 March 2022 - 30 September 2023 (19 months)
LSNE: 1 March 2022 - 31 January 2023 (11 months)
NWLN: 1 March 2022 - 31 January 2023 (11 months)

Oral Products plus non-parenterals
All Regions: 1 March 2022 - 31 May 2024 (27 months)

Hospital Only Products
CESW: 1 February 2022 - 30 September 2023 (20 months)
LSNE: 1 February 2022 - 31 May 2024 (28 months)
NWLN: 1 February 2022 - 31 January 2023 (12 months)

### Lot Information

Lot 1 - CM/PHG/17/5532/00 Transition (Everolimus)

Invitation to offer for NHS National Generic Pharmaceuticals Wave 13
Offer reference number: CM/PHG/17/5532
Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.

Potential periods of call-offs under the framework agreement:

Transition (Everolimus)
CESW: 1 March 2022 - 30 September 2023 (19 months)
LSNE: 1 March 2022 - 31 January 2023 (11 months)
NWLN: 1 March 2022 - 31 January 2023 (11 months)

Oral Products plus non-parenterals
All Regions: 1 March 2022 - 31 May 2024 (27 months)

Hospital Only Products
CESW: 1 February 2022 - 30 September 2023 (20 months)
LSNE: 1 February 2022 - 31 May 2024 (28 months)
NWLN: 1 February 2022 - 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: Option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.

Lot 2 - CM/PHG/17/5532/01 Oral Products plus non-parenterals

Invitation to offer for NHS National Generic Pharmaceuticals Wave 13
Offer reference number: CM/PHG/17/5532
Period of framework agreement:The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.

Potential periods of call-offs under the framework agreement:

Transition (Everolimus)
CESW: 1 March 2022 - 30 September 2023 (19 months)
LSNE: 1 March 2022 - 31 January 2023 (11 months)
NWLN: 1 March 2022 - 31 January 2023 (11 months)

Oral Products plus non-parenterals
All Regions: 1 March 2022 - 31 May 2024 (27 months)

Hospital Only Products
CESW: 1 February 2022 - 30 September 2023 (20 months)
LSNE: 1 February 2022 - 31 May 2024 (28 months)
NWLN: 1 February 2022 - 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: Option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.

Lot 3 - CM/PHG/17/5532/02 Hospital Only Products

Invitation to offer for NHS National Generic Pharmaceuticals Wave 13
Offer reference number: CM/PHG/17/5532
Period of framework agreement: The total maximum duration of the framework agreement to be no more than 28 months, with an option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.

Potential periods of call-offs under the framework agreement:

Transition (Everolimus)
CESW: 1 March 2022 - 30 September 2023 (19 months)
LSNE: 1 March 2022 - 31 January 2023 (11 months)
NWLN: 1 March 2022 - 31 January 2023 (11 months)

Oral Products plus non-parenterals
All Regions: 1 March 2022 - 31 May 2024 (27 months)

Hospital Only Products
CESW: 1 February 2022 - 30 September 2023 (20 months)
LSNE: 1 February 2022 - 31 May 2024 (28 months)
NWLN: 1 February 2022 - 31 January 2023 (12 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: Option or options to extend (at the Authority's sole discretion) for a period or periods up to a total of 48 months.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/001128-2022 |
| Notice type | Tender Notice |
| Procurement type | Framework |
| Procurement category | Goods |
| Procurement method | Open |
| Procurement method details | Open procedure |
| Tender suitability | Not specified |
| Awardee scale | Large, SME |
| All stages | Tender, Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 14 Jan 2022 |
| Submission deadline | 26 Jul 2021 |
| Future notice date | Not specified |
| Award date | 30 Nov 2021 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | £1,637,875,080 |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £1 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Cancelled |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND) |
| Locality | RUNCORN |
| Post town | Warrington |
| Postcode | WA7 2ES |
| Country | England |
| ITL 1 | TLD North West (England) |
| ITL 2 | TLD7 Merseyside |
| ITL 3 | TLD71 East Merseyside |
| Local authority | Halton |
| Electoral ward | Halton Lea |
| Westminster constituency | Runcorn and Helsby |
| Delivery location | Not specified |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 131 |
| Supplier names | ACCORD-UK; ACIUM; AGUETTANT; ALISSA HEALTHCARE RESEARCH; ALLERGAN; ALLIANCE PHARMACEUTICALS; ALTAN PHARMA; ALTURIX; AMAROX; AOP ORPHAN; ARCADIA PHARMA LTD T/A ARCADIA MEDICAL; ARISTO PHARMA; ASCEND LABORATORIES; ASPEN PHARMACARE; ASPIRE PHARMA; ATNAHS PHARMA; AVENTIS PHARMA LTD T/A SANOFI; B. BRAUN MEDICAL; BAXTER HEALTHCARE; BAYER; BEAUMONT PHARMA; BOWMED IBISQUS; BRISTOL LABORATORIES; BROWN AND BURK; CHIESI; CIPLA (EU; CLYDESDALE PHARMA; COLONIS PHARMA; CONSILIENT HEALTH; CORREVIO; CRESCENT PHARMA; CST PHARMA; DAY LEWIS MEDICAL; DERMA; DESITIN PHARMA; DEXCEL PHARMA; DR FALK PHARMA; DR.REDDY'S LABORATORIES (UK; DRUGSRUS; ENNOGEN HEALTHCARE; EURO-LINK PHARMA; FERNDALE PHARMACEUTICALS; FERRING PHARMACEUTICALS; FLEXIPHARM AUSTRADING; FLYNN PHARMA; FOCUS PHARMACEUTICALS; FONTUS HEALTH; FRESENIUS KABI; GALEN; GLAXOSMITHKLINE; GLENMARK PHARMACEUTICALS EUROPE; HAMELN PHARMA; HEALTHCARE PHARMA; INTRAPHARM LABORATORIES; IPCA LABORATORIES; KENSINGTON PHARMA; KENT PHARMA; KYOWA KIRIN; LABORATORIO REIG JOFRE; LEO PHARMA; LOGIXX PHARMA; LUCANE PHARMA; LUNDBECK; LUPIN HEALTHCARE (UK; MACLEODS PHARMA; MACURE PHARMA; MANX HEALTHCARE; MARTINDALE PHARMA; MEDAC PHARMA; MEDLEY PHARMA; MEDREICH; MERCK SHARPE AND DOHME (UK; MERCURY PHARMACEUTICALS; MIBE PHARMA; MILPHARM LTD/AUROBINBDO; MIP PHARMA; MORNINGSIDE PHARMAEUTICALS; MYLAN; NAPP PHARMACEUTICALS; NECESSITY SUPPLIES; NEON HEALTHCARE; NEXCAPE PHARMACEUTICALS; NORGINE PHARMACEUTICALS; NORTHUMBRIA PHARMA; NOUMED LIFE SCIENCES; ORALIEVE; ORGANON PHARMACEUTICALS; P M PHARMA; PANPHARMA; PARI; PFIZER; PHOENIX LAB; PIERRE FABRE; PROFILE PHARMA; RANBAXY; RECORDATI PHARMACEUTICALS; RECORDATI RARE DISEASES; RELONCHEM; RIVOPHARM; ROCHE PRODUCTS; ROMA PHARMACEUTICALS; ROSEMONT PHARMACEUTICALS; RPH PHARMACEUTICALS; SANDOZ; SCIECURE PHARMA; SEACROSS PHARMACEUTICALS; SELECTIVE SUPPLIES; SINTETICA; SOBI (SWEDISH ORPHAN BIOVITRUM; STRAGEN; STRIDES PHARMA; SYNCHRONY; SYRI LIMITED (T/A THAME LABORATORIES; TAKEDA; TETRIS PHARMA LTS; TEVA; THEA PHARMACEUTICALS; THORNTON AND ROSS; TILLOMED LABORATORIES; TORBAY PHARMACEUTICALS; TORRENT PHARMA; TRANSDERMAL; TYPHARM; UPJOHN; V PHARMA; VANTAGE PHARMACEUTICALS; WAVERLEY PHARMA EUROPE; WAYMADE; WOCKHARDT; ZENTIVA PHARMA; ZISTA PHARMA |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33600000 - Pharmaceutical products

## Release History

- 14 Jan 2022 at 10:31 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/001128-2022
- 21 Jun 2021 at 10:23 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/014005-2021

## Notice URLs

- http://health.atamis.co.uk
- http://health.atamis.co.ukCandidates
- https://supplierregistration.cabinetoffice.gov.ukand
- https://www.england.nhs.uk/
- https://www.gov.uk/courts-tribunals

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02be28. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-02be28.json.